Ligand Pharmaceuticals (LGND) on the Upswing: AI Predicts 4% Monthly Growth despite Bearish Signals
Despite recent bearish indicators, Ligand Pharmaceuticals (LGND, $71.7) has shown resilience and is forecasted to grow by 4% to $74.57 or more within the next month. Our trusty AI advisor, after considering numerous scenarios where the stock trended up over the month, puts the odds of this uptrend continuation at a promising 76%.
Discover the revolutionary potential of AI-driven trading decisions with Tickeron's advanced technology.
This outlook comes amidst challenging circumstances. The biotechnology industry, in which Ligand operates, shows an average market capitalization of 2.08B. Across the sector, market caps range from a modest 402 (PNEXF) to a whopping 345.46B (NONOF). Despite this vast disparity, Ligand has managed to hold its ground and show potential for growth.
Over the past week, the biotech sector exhibited a price growth of -3%. Looking further into the past, monthly price growth averaged 1%, while the quarterly growth reached 30%. The sector saw considerable volatility, with AGLE showcasing the highest price growth at an impressive 257% and AVTX experiencing the sharpest fall at -89%.
Furthermore, the volume growth in the industry has been dipping with weekly, monthly, and quarterly growth rates of -30%, -15%, and -75% respectively. Despite this overall reduction in trading activity, Ligand continues to make strides.
However, it's worth noting that LGND has seen a downward trend recently, with its 10-day moving average moving below the 50-day moving average on June 28, 2023. This crossover, typically considered a bearish signal, indicates that the trend may have shifted downwards. In previous instances where the 10-day average crossed below the 50-day, the stock continued to move higher over the following month in 13 out of 14 cases.
Although this suggests a 90% chance of a continued downward trend, the resilience and positive growth prediction for Ligand provide a compelling counter-narrative. Ligand Pharmaceuticals' ability to defy odds and expectations sets it apart, making it a stock to watch closely in the coming weeks.
Stay tuned as we continue to monitor these market movements and provide timely insights to help guide your investment decisions. At Tickeron, we believe in unleashing the power of artificial intelligence to enhance trading decisions, and our marketing team plays a pivotal role in sharing this vision with the world
LGND in upward trend: price rose above 50-day moving average on January 21, 2026
LGND moved above its 50-day moving average on January 21, 2026 date and that indicates a change from a downward trend to an upward trend. In of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on January 14, 2026. You may want to consider a long position or call options on LGND as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for LGND just turned positive on January 22, 2026. Looking at past instances where LGND's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for LGND crossed bullishly above the 50-day moving average on January 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LGND advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 246 cases where LGND Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for LGND moved out of overbought territory on January 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGND declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
LGND broke above its upper Bollinger Band on January 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LGND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.167) is normal, around the industry mean (27.560). P/E Ratio (88.612) is within average values for comparable stocks, (51.229). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.889). Dividend Yield (0.000) settles around the average of (0.056) among similar stocks. P/S Ratio (15.601) is also within normal values, averaging (317.994).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company
Industry Biotechnology
Advertisement